Instil Bio, Inc. TIL
6.99 USD 0.00 (+0.00%)
At closeNov 5, 2026, 4:00 PM EST
6.99 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
6.70 Day range 7.13
5.56 52-week range 16.00
- YTD
- -36.45%
- 1 year
- -54.73%
News
globenewswire.com Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned…
globenewswire.com Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
globenewswire.com Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both…
globenewswire.com Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral…
globenewswire.com Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously…
gurufocus.com Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
marketbeat.com Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter…
zacks.com 5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and…
benzinga.com Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 84.37 percent increase over losses of $(2.88)…
globenewswire.com Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second…
gurufocus.com Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
seekingalpha.com Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy) Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
globenewswire.com Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a…
benzinga.com Earnings Scheduled For May 15, 2026 
globenewswire.com Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first…- benzinga.com Earnings Scheduled For March 27, 2026
benzinga.com Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08)…
globenewswire.com Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current…
globenewswire.com Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to…
benzinga.com Dow Jumps Over 400 Points; US Services Activity Falls In December 
benzinga.com Instil Bio Pulls Plug On Lead Drug Development Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new questions about its pipeline and next steps.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com US Stocks Mixed; Nasdaq Gains Over 50 Points - benzinga.com Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.75) per share which beat the analyst consensus estimate of $(2.35) by 25.69 percent. This is a 31.37 percent increase over losses of $(2.55)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com Instil Bio Says ImmuneOnco Biopharma Presents Preliminary Efficacy And Safety Data Of '2510 As Monotherapy In Phase 1 Study Of Patients In China With Previously Treated Sq-NSCLC At 2025 WCLC ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC…- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com JMP Securities Reiterates Market Perform on Instil Bioto Market Perform JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $105 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target from $110 to $105.
- benzinga.com Instil Bio, ImmuneOnco Advance Lung Cancer Drug '2510 With New Trials in China and US Plans Ahead Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced clinical trial updates of ‘2510 and NSCLC clinical…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket 
benzinga.com Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by 49.03 percent. This is a 44.77 percent increase over losses of $(2.39)…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $110 price target.
benzinga.com Instil Bio Q4 2024 GAAP EPS $(1.82) Beats $(3.22) Estimate, Instil Had $115.1M In Total Cash, Cash Equivalents, Restricted Cash And Marketable Securities, That Is Expected To Fund Its Current Operating Plan Beyond 2026 Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(3.22) by 43.48 percent. This is a 8.54 percent increase over losses of $(1.99)…- benzinga.com JMP Securities Reiterates Market Perform on Instil Bioto Market Perform JMP Securities analyst Chris Muller reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
- benzinga.com Instil Bio Announces Clinical Progress In China For IMM2510/SYN-2510, A Clinical-Stage PD-L1xVEGF Bispecific Antibody ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China.